

About Acrux

About Acrux

Board of
Directors

Management
Team

Company
Philosophy

Partnering
with us

Contact Us

[Acrux](#) / [About Acrux](#)

About Acrux

Acrux ([ASX](#): ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals.

Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, [GMP](#) manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

Products and technology

Currently, we have three pharmaceutical products approved and marketed and are investing in research to develop further products to meet patients' needs. [Learn more about our commercialised products.](#)

Acrux's proprietary technology is covered by broad, well-differentiated, issued patents. We continue to develop this technology, expanding the breadth of molecules which can be administered topically.

Facilities and capabilities

With onsite laboratories and a [GMP](#) manufacturing facility, we can oversee our products from early development through to clinical trials. We hold a [TGA](#) licence for the manufacture of transdermal and transmucosal products for clinical trials.

Our development processes include, but are not limited to:

- Analytical method development and validation
- Container closure selection
- Applicator or device development
- Extractables and leachables testing
- Stability testing
- Manufacturing scale-up and technical transfer to commercial-scale facilities
- Performing [CMC](#) activities, studies and reports for regulatory submissions


Shareholders

Acrux Limited is a listed entity on the [ASX](#) and is a Pooled Development Fund, registered under the Pooled Development Fund Act 1992.

Under the Pooled Development Fund Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed.

An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

ACRUX TIMELINE



First US patent granted

2004



Acrux listed on [ASX](#)
(ACR:ASX)

2008



Evamist[®] launched by KV
Pharmaceutical

Acrux initiates Axiron[®] Phase
III clinical trial

2011



Axiron[®] launched by Eli Lilly

2014



Veterinary licensed to Elanco
globally (including
Recuvra[®])

2007



Evamist[®] licensed to KV
Pharmaceutical in US

2010



Acrux submits Axiron[®] [NDA](#)
to [FDA](#)

Axiron[®] licensed to Eli Lilly

2013



Recuvra[®] launched by
Elanco



Evamist® licensed to Perrigo
in US

Estradiol licensed to Gedeon
Richter; including for EU

2016



Lenzetto® launched in Europe

Subscribe now to receive company announcements